tbuckley/cabot-search huggingface dataset:
FRI0424 Accessibility To Biological Therapy for Patients with Ankylosing Spondylitis in Romania Is Influenced by Area of Residence, Socio- Economic and Demographic Factors
Authors: L. Enache, C. Codreanu, C. Mogosan, G. Gutoiu, C. Popescu, M. Parvu, S. Rednic, R. Ionescu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The efficacy of anti TNFblockers in active ankylosing spondylitis (AS) is widely accepted. In Europe, high costs related to biological treatment lead to significant differences regarding the patient9s accessibility to treatment depending on the level of economic development of different countries. In Romania, according to the national reimbursement protocol, a patient is eligible for treatment with TNF blockers if the disease is active despite using at least two non-steroidal anti-inflammatory drugs and sulfasalazine (for peripheral arthritis). <h3>Objectives</h3> The aim of the study is to assess the accessibility of patients with AS to biological therapy in Romania, depending on their area of residence and socio- economical indicators for each region. <h3>Methods</h3> A cross-sectional study was performed in 41 counties and Bucharest. Data were collected from the Romanian Registry of Rheumatic Diseases and the socio- economic indicators from the yearbook of the National Institute for Statistics. <h3>Results</h3> Data were gathered for 2013 AS patients treated with biologics. The mean age was 45.46 yrs (±12.07), 78% were male, 71% live in urban residences and the mean disease duration was 11.53 yrs. 74% (n=1498) of patients had access to biologics in their county of residence, while 26% (n=524) of patients had to travel for treatment to another county. Compared to the group treated inside their county of residence, those treated outside, originated from areas with a lower gross domestic product per capita (5701.77 € compared to 8722.44 €; p&lt;0.001; t test) and with high deficit of physicians (1.28 physicians/ 1000 inhabitants, comparated to 2.63 physicians/ 1000 inhabitants; p&lt;0.001; t test). The urban habitat was associated with a higher accessibility to biologics (75.9%) inside their county of residence compared to patients living in rural areas (69.2%) (p=0.002, χ<sup>2</sup> test); so the latter have to travel in order to being cared by a rheumatologist. The patients9 age had a great influence on the accessibility to biologics: the patients treated outside of their county of residence were younger than those treated inside (44.1 yrs compared to 45.9 yrs; p=0.003, t test). On a national scale, the majority of AS patients treated outside their county of residence (86%; 449); were treated in Bucharest (the capital city); so the majority of patients treated with biologics in Bucharest are originating from other counties (60%; n=449/751). <h3>Conclusions</h3> In Romania, although there is a national protocol for biological therapy in AS, applied in the same way in every region of the country, the accessibility to biologic therapy varies a lot, mostly due to differences in the socio- economic status of each area of residence. <h3>Disclosure of Interest</h3> None declared
Endoscopic ultrasound-guided gallbladder drainage reduces adverse events compared with percutaneous cholecystostomy in patients who are unfit for cholecystectomy
Authors: Anthony Teoh, Carlos Serna, Irene Penas, Charing Chong, Manuel Perez-Miranda, Enders Ng, James Lau
Journal: Endoscopy (2016)

<b>Background and study aim</b> There are no data comparing endoscopic ultrasound (EUS)-guided gallbladder drainage (EGBD) with percutaneous cholecystostomy as a treatment for patients with acute cholecystitis. <b>Patients and methods</b> This was a 1 : 1 matched cohort study of all patients who were unfit for cholecystectomy and underwent EGBD or percutaneous cholecystostomy instead for the treatment of acute cholecystitis. The outcomes were matched for age, sex, and American Society of Anesthesiologists grade. Outcome measures included the technical and clinical success rates, adverse events, hospital stay, the number of unplanned admissions, and mortality. <b>Results</b> Between November 2011 and August 2014, a total of 118 patients were included in the study (59 EGBD, 59 percutaneous cholecystostomy). Technical and clinical success rates were similar. In the EGBD group, significantly fewer patients suffered from overall adverse events (19 [32.2 %] vs. 44 [74.6 %]; <i>P</i> < 0.001) and serious adverse events (14 [23.7 %] vs. 44 [74.6 %]; <i>P</i> < 0.001) compared to the percutaneous cholecystostomy group. Patients in the EGBD group required fewer unplanned admissions (4 [6.8 %] vs. 42 [71.2 %]; <i>P</i> < 0.001), which were due to problems related to the cholecystostomy tube in 95.2 %. The 30-day adverse event rates were similar between the groups (17 [28.8 %] vs. 10 [16.9 %]; <i>P</i> = 0.13). For instance, recurrent acute cholecystitis occurred in 0 patients in the EGBD group and in 4 (6.8 %) patients in the percutaneous cholecystostomy group (<i>P</i> = 0.12). The 30-day mortality rates were non-significantly higher in the EGBD group (5 [8.5 %] vs. 1 [1.7 %]; <i>P</i> = 0.21). <b>Conclusions</b> EGBD and percutaneous cholecystostomy were both effective means of achieving gallbladder drainage. EGBD may be a promising alternative to percutaneous cholecystostomy for treatment of acute cholecystitis in patients who are unfit for surgery, provided that experienced endosonographers are available.
PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.
Authors: Ivana N. Micallef, Matthew J. Maurer, Thomas E. Witzig, Daniel Nikcevich, Paul Kurtin, Michael W. Cannon, Patrick J. Flynn, Gamini S. Soori, Val Lowe, Gregory Wiseman
Journal: Blood (2009)
Risk Scores From PARIS Registry
Authors: Sergio Raposeiras-Roubín, Emad Abu-Assi, Lucía Rioboó-Lestón, Juan Ocampo Míguez, Rafael Cobas Paz, Berenice Caneiro Queija, Francisco Calvo Iglesias, Andrés Iñiguez-Romo
Journal: Journal of the American College of Cardiology (2016)
Poor Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for De Novo AML with Chromosome 7 Abnormalities: A Report for the ALWP of the European Group for Blood and Marrow Transplantation.
Authors: Agnes Buzyn, Myriam Labopin, Jurgen Finke, Tapani Ruutu, G. Ehninger, Leo F. Verdonck, Gerard Socie, Roelof Willemze, Karel Indrak, Nigel H. Russell, Vanderson Rocha
Journal: Blood (2007)
Treatment of Adult Acute Lymphoblastic Leukemia (ALL) with a Modified DFCI Pediatric Regimen - The Princess Margaret Experience.
Authors: John M. Storring, Joseph Brandwein, Vikas Gupta, Andre C. Schuh, Aaron Schimmer, Karen Yee, Richard A. Wells, Jeffrey H. Lipton, Hans A. Messner, Wei Xu, Mark D. Minden
Journal: Blood (2006)
Transient Massive Lymphoid Bone Marrow Infiltrate Developing during Therapy with the Tyrosine Kinase Inhibitors Imatinib and Nilotinib: Report of 2 Patients.
Authors: Ester Pungolino, Silvia Cantoni, Cecilia Del Curto, Livio Gargantini, Marianna Caramella, Sara Miqueleiz, Alessandra Tedeschi, Michela Draisci, Cristina Gabutti, Simona Paratore, Karen Lanza, Sonia Ribera, Enrica Morra
Journal: Blood (2007)
AB0714 Nsaid Prescribing Practice in Patients with Spondyloarthritis
Authors: S. Habibi, R. Sengupta
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> NSAID9s are widely prescribed for patients with active spondyloarthritis. All NSAID9s have the risks of adverse cardiovascular, GI, renal and thrombotic toxicity. The Medicines and Healthcare Products Regulatory Authority (MHRA) as well as National Institute of Clinical Excellence (NICE) have issued guidance that applies to all traditional NSAIDs and selective COX-2 inhibitors. <h3>Objectives</h3> To review the prescribing of NSAID9s in line with the MHRA/NICE recommendations. <h3>Methods</h3> This is a Trust-wide audit, looking into the NSAID prescribing practice in spondyloarthritis at the Royal National Hospital for Rheumatic Diseases. The "AS database" was interrogated to define the total number of patients prescribed an NSAID to be taken continuously, from 1st Sept 2014 till 31st Aug 2015. Data was retrospectively collected from the database as well as the case records. Information regarding the definite indication for NSAID prescribed, contraindications and risk factors was collected. Pathology systems were accessed to check if renal function had been performed in the past 12 months of prescription. <h3>Results</h3> 69 patients with SpA taking regular NSAIDs were identified. A clear indication was identified in 44/69 (63.7%) patients (Table 1). No patients with contra-indications were prescribed the drugs. 22/69 (31.8%) had one or more risk factors for the drugs (Table 2). 49/69 (71.01%) patients were at risk of adverse GI effects. Of these, 27 (55.1%) were prescribed PPI9s. Renal function in the last 12 months was assessed in 40/69 (57.97%) patients. 8 patients who were receiving other concomitant nephrotoxic drugs had not had their renal function assessed in the past 12 months. <h3>Conclusions</h3> The proportion of patients with a documented indication for NSAID was moderately high. No patients with contra-indications to the drugs were prescribed the medication, which is in keeping with the guidance. The most common risk factors were age&gt;65 years, hypertension and drug interactions involving ACE-I and ARB9s, which increase the risk of nephrotoxicity. Only 55% of those at risk of adverse GI side effects were prescribed a PPI. Monitoring of renal function in addition, was moderate, being done in just over a half of the patients. Strategies to improve routine assessment of risk factors prior to commencing NSAIDs in AxSpA patients need to be addressed. <h3>Disclosure of Interest</h3> None declared
Neurofibromatosis Type 1 (NF1), a Tumor Suppressor Gene, Is Synergistically Activated by RUNX1, C/EBPαa and ETS2 and Specifically Repressed by the T(8;21) Fusion Protein in Acute Myeloid Leukemia.
Authors: Genyan Yang, Waleed Khalaf, Wade D. Clapp, Scott W. Hiebert
Journal: Blood (2004)
Early Immune Recovery Predicts Overall and Disease-Free Survival After Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Jenna D. Goldberg, Junting Zheng, Juliet Barker, Farid Boulad, H.R. Castro-Malaspina, Katharine C Hsu, Ann Jakubowski, Nancy Kernan, Richard J O'Reilly,, Esperanza Papadopoulos, Susan Prockop, Andromachi Scaradavou, Marcel van den Brink, James Young, Glenn Heller, Miguel-Angel Perales
Journal: Blood (2009)
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
Authors: Gadi Shlomai, Brian Neel, Derek LeRoith, Emily Jane Gallagher
Journal: Journal of Clinical Oncology (2016)

Purpose Type 2 diabetes mellitus (T2DM) is becoming increasingly prevalent worldwide. Epidemiologic data suggest that T2DM is associated with an increased incidence and mortality from many cancers. The purpose of this review is to discuss the links between diabetes and cancer, the effects of various antidiabetic medications on cancer incidence and mortality, and the effects of anticancer therapies on diabetes. Design This study is a review of preclinical and clinical data regarding the effects of antidiabetic medications on cancer incidence and mortality and the effects of anticancer therapies on glucose homeostasis. Results T2DM is associated with an increased risk and greater mortality from many cancer types. Metformin use has been associated with a decrease in cancer incidence and mortality, and there are many ongoing randomized trials investigating the effects of metformin on cancer-related outcomes. However, data regarding the association of other antidiabetes medications with cancer incidence and mortality are conflicting. Glucocorticoids, hormone-based therapies, inhibitors that target the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway, and insulin-like growth factor 1 receptor–targeted therapy have been associated with high rates of hyperglycemia. These agents mediate their deleterious metabolic effects by reducing insulin secretion and increasing insulin resistance in peripheral tissues. Conclusion Studies must be performed to optimize cancer screening strategies in individuals with T2DM. A greater understanding of the mechanisms that link diabetes and cancer are needed to identify targets for therapy in individuals with diabetes who develop cancer. Data from clinical studies are needed to further elucidate the effects of antidiabetic medications on cancer incidence and progression. As several anticancer therapies alter glucose homeostasis, physicians need to be aware of these potential effects. Careful patient screening and monitoring during treatment with these agents is necessary.
Interim [18F]Fluorodeoxyglucose Positron Emission Tomography SUVmax Reduction Is Superior to Visual Analysis to Predict Early patient's Outcome In Diffuse Large B-Cell Lymphoma
Authors: Rene-Olivier Casasnovas, Michel Meignan, Alina Berriolo-Riedinger, Stephane Bardet, Anne Julian, Catherine Thieblemont, Pierre Vera, Serge Bologna, Josette Briere, Jean-Philippe Jais, Corinne Haoiun, Bertrand Coiffier, Franck Morschhauser
Journal: Blood (2010)
Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination
Authors: Jiwon Lee, Daniel R Boutz, Veronika Chromikova, M Gordon Joyce, Christopher Vollmers, Kwanyee Leung, Andrew P Horton, Brandon J DeKosky, Chang-Han Lee, Jason J Lavinder, Ellen M Murrin, Constantine Chrysostomou, Kam Hon Hoi, Yaroslav Tsybovsky, Paul V Thomas, Aliaksandr Druz, Baoshan Zhang, Yi Zhang, Lingshu Wang, Wing-Pui Kong, Daechan Park, Lyubov I Popova, Cornelia L Dekker, Mark M Davis, Chalise E Carter, Ted M Ross, Andrew D Ellington, Patrick C Wilson, Edward M Marcotte, John R Mascola, Gregory C Ippolito, Florian Krammer, Stephen R Quake, Peter D Kwong, George Georgiou
Journal: Nature Medicine (2016)
Abstract 15706: Pregnancy Outcome After Preconcpetion Evaluation in Women With Heart Disease
Authors: Marla A Mendelson, Lauren A Davis, Adin-Christian Andrei
Journal: Circulation (2015)

Background: Cardiovascular disease is the leading cause of maternal mortality in pregnancy in western countries. The number of women with preexisting cardiac disease desiring pregnancy is increasing; therefore, preconception evaluation to assess maternal and fetal risks can determine necessary interventions prior to conception to improve outcome. Objectives: This observational pilot study sought to determine pregnancy outcomes in women with heart disease after preconception evaluation. Methods: Clinical records of women who had preconception evaluations at Bluhm Cardiovascular Institute between 1996 and 2012 were retrospectively reviewed. Results: Of the 400 women who had preconception evaluation, 276 had subsequent pregnancies. Maternal diagnoses and clinical outcomes are summarized in Table 1 and Table 2. Preconception procedures were required in 20 patients: atrial septal defect repair (7); arrhythmia ablation (6); valve replacement (3); pacemaker insertion (2) and coronary revascularization (2). Medication changes were recommended in 32% of women. The 276 pregnancies resulted in 178 live births (112 (64%) vaginal, 63 (36%) cesarean), 45 fetal deaths (85% spontaneous abortions or ectopic pregnancies), and 53 unknown outcomes. Congenital heart disease was diagnosed in 4 (2.3%) of the offspring. None of the women developed clinically significant cardiac complications. Conclusion: We describe pregnancy outcomes in women with varied heart disease diagnoses and disease severity who had preconception evaluation. Preconception evaluation may afford the opportunity to improve clinical outcome for mother and baby in women with preexisting heart disease.
The Reduction of Leukemic Blasts in Bone Marrow Aspirate on Day 6 of Remission Induction Treatment Is Predictive for Complete Remission Rate and Survival in Adult Acute Myeloid Leukemia; the Results of Multicenter, Prospective Polish Adult Leukemia Group Trial.
Authors: Jerzy Holowiecki, Sebastian Grosicki, Slawomira Kyrcz-Krzemien, Kazimierz Kuliczkowski, Marek Kielbinski, Aleksander B. Skotnicki, Beata Jakubas, Andrzej Hellmann, Tadeusz Robak, Marek J. Seweryn, Beata Stella-Holowiecka, Maria Sadus-Wojciechowska
Journal: Blood (2007)
AB0967 Ultrasonographic Features of Neuropathic (Charcot) Arthropathy of Ankle Joint
Authors: M. Mortada, M.A.H. Hammad, N. Ezzeldin
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> neuropathic osteoarthropathy (Charcot arthropathy) is a progressive condition that is characterized by joint dislocations, pathologic fractures, and debilitating deformities. It occurs most commonly in the lower extremity, at the foot and ankle. Although magnetic resonance imaging (MRI) is the modality of choice to examine patients with suspected neuropathic osteoarthropathy, for its ability to depict bone and soft tissues changes, ultrasonography (US) may be able to identify pathological changes in cases of Charcot arthropathy. Up to the best of our knowledge this the first study of ultrasonographic feature of neuropathic ankle joint. <h3>Objectives</h3> Our aim was to characterize the ultrasonographic features of patients with neuropathic (Charcot) arthropathy of ankle joint. <h3>Methods</h3> In this retrospective study, all 26 patients between January 2013 and December 2015 with neuropathic (Charcot) arthropathy of ankle joint proved by X ray and/or MRI were enrolled. We collected and analyzed 26 patients, on whom high-resolution (5–15 MHz) muculoskeletal US of ankle and small joints of the affected feet had been carried out. <h3>Results</h3> Ages of our patients ranged from 38 to 67years (57.3± 6.4). Most of our patients (25 patients) 96.2% had diabetes mellitus and all of our patients had peripheral neuropathy. According to the modified Eichenholtz classification system; 3 patients (11.5%) were in grade 0, 11 patients (42.3%) were in grade 1, 10 patients (38.5%) were in grade 2, and 2 patients (7.7%) were in grade 3. Ultrasonographic findings were: Effusion/synovitis of ankle joints (100%), High Doppler activity (grade 2 or 3) in ankle joint was present in 92.3% of our patients, bone irregularities in distal fibula 73.1%, bone irregularities in distal tibia were found in 34.6%, tendonitis of tibialis posterior 65.4%, proneal tendonitis were found in 50%. Double contour sign were present in 2 ankle joints (7.7%). Arthritis (effusion/synovitis) in mid tarsal joints were found in 92.3% of patients with high Doppler activity in 65.4% and bone irregularities in57.7%. <h3>Conclusions</h3> The main US features of neuropathic (Charcot) arthropathy of ankle joint are: effusion, synovitis, high grade Doppler activity, bone irregularities of the distal fibula and involvement of mid tarsal joints (synovitis, high Doppler activity and bone irregularities). <h3>Disclosure of Interest</h3> None declared
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia
Authors: Sieghart Sopper, Satu Mustjoki, Deborah White, Timothy Hughes, Peter Valent, Andreas Burchert, Bjørn T. Gjertsen, Günther Gastl, Matthias Baldauf, Zlatko Trajanoski, Frank Giles, Andreas Hochhaus, Thomas Ernst, Thomas Schenk, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Kimmo Porkka, Dominik Wolf
Journal: Journal of Clinical Oncology (2017)

Purpose Immunologic surveillance of minimal residual disease in chronic myelogenous leukemia (CML) may be relevant for long-term control or cure of CML. Little is known about immune-modulatory effects of nilotinib in vivo, potentially predicting response to therapy. Patients and Methods A prospective and comprehensive flow cytometry-based immunomonitoring program paralleled the ENEST1st clinical study, investigating 52 nilotinib-naïve patients with chronic-phase CML. Data were verified in independent validation cohorts. Results T cells of patients with CML at diagnosis expressed low l-selectin (CD62L) levels, which was not a result of proportional aberrations of T-cell subsets. Low numbers of CD62L-expressing CD4+ and CD8+ T cells correlated with higher Sokal score, increased spleen size, and high leukocyte and peripheral-blood blast counts. At month 6 during nilotinib therapy, CD62L expression returned to levels of healthy individuals. The level of CD62L loss on T cells directly correlated with the extent of soluble CD62L (sCD62L) elevation. In parallel, the proteolytic activity of tumor necrosis factor α-converting enzyme (TACE; ADAM17, CD156b), the metalloproteinase shedding CD62L, was increased at diagnosis and significantly decreased during nilotinib treatment. High CD62L+ expression on both CD4+ and CD8+ T cells and, vice versa, low sCD62L levels at CML diagnosis were linked to superior molecular responses. These findings were corroborated in independent validation cohorts. Conclusion We demonstrate the prognostic impact of CD62L shedding from T cells and increased sCD62L plasma levels at CML diagnosis on molecular response to tyrosine kinase inhibitor therapy in early chronic-phase CML. Functionally, decreased CD62L may be a consequence of increased TACE-mediated CD62L cleavage and potentially impairs immune-cell function. Larger prospective studies are ongoing to confirm the prognostic relevance of this finding.
Senator Confronts FDA Over Laboratory Tests
Authors: Jeff Lyon
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reduced Incidence of Acute Graft Versus Host Disease (GVHD) and Transplant-Related Mortality (TRM) with the Addition of Short-Course Mini-Dose Methotrexate (MTX) to Cyclosporine (CSA) as GVHD Prophylaxis Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).
Authors: Ramaprasad Srinivasan, Haley Hedlin, Rose Goodwin, Aleah Smith, Catalina Ramos, Lisa Cook, Charles Bolan, Hisayuki Yokoyama, Shivani Srivastava, Jennifer Karpovich, Teresa Donohue, John Barrett, Nancy Geller, Richard Childs
Journal: Blood (2007)